Profile: Amgen Inc. produces novel products based on advances in recombinant DNA and molecular biology. Our product AMG 191 is a humanized anti-c-kit monoclonal antibody that inhibits the binding of stem cell factor (SCF) to c-kit. Inhibition of SCF binding may have potential therapeutic benefit in a variety of inflammatory diseases. Our product neulasta® is a recombinant protein that stimulates the production of infection-fighting white blood cells called neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia. Our product vectibix® is indicated as a single agent for the treatment of patients with EGFr-expressing metastatic colorectal cancer.